Company: LDDD
Filing Date: 2025-02-14
Form Type: 10-Q
Source: 0001213900-25-013782
Chunk: 212

Company: Longduoduo Co Ltd
Filing Date: 2025-02-14
Form: 10-Q
Item: Part II, Item 8
Chunk 212
---
,544,567  
    $3,927,976  
    $(1,383,409) 
     (35)%
  
    Cost of revenue 
     61,057  
     104,750  
     (43,693) 
     (42)%
  
    Gross Profit 
     2,483,510  
     3,823,226  
     (1,339,716) 
     (35)%
  
    Total operating expenses 
     1,943,012  
     2,993,459  
     (1,050,447) 
     (35)%
  
    Loss from operations 
     540,498  
     829,767  
     (289,269) 
     (35)%
  
    Other income (expense), net 
     8,173  
     (135,222) 
     143,395  
     (106)%
  
    Loss before income taxes 
     548,671  
     694,545  
     (145,874) 
     (21)%
  
    Income tax 
     106,576  
     216,973  
     (110,397) 
     (51)%
  
    Net income 
    $442,095  
    $477,572  
    $(35,477) 
     (7)%

During the six months ended December 31, 2024, our total revenue was
$2,544,567, of which $61,057 was attributable to the sale of healthcare services, primarily derived from sales of “Immunological
Ozonated Autohemotherapy”, “Meridian-regulating and Consciousness-restoring Iatrotechnics”, “Assay”, “PRP”
and other healthcare services. The remaining $2,544,567 of revenue was attributable to commissions earned by the Company from its service
as sales agent for Honghai. In June of 2023, the Company began to engage in the sales agent business and focused on the sales of preventive
healthcare solutions administered by Honghai, with whom we have a Sales Agency Agreement. As of December 31, 2024, we operate through
five entities: Longduoduo Health Technology, Tianju, Qingguo, Rongbin and Chengheng,